Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Celularity (CELU) EBIT (2020 - 2025)

Celularity (CELU) has disclosed EBIT for 6 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • For Q4 2025, EBIT rose 315.32% year-over-year to $20.0 million; the TTM value through Dec 2025 reached -$19.3 million, up 49.77%, while the annual FY2025 figure was -$19.3 million, 49.77% up from the prior year.
  • EBIT hit $20.0 million in Q4 2025 for Celularity, up from -$12.9 million in the prior quarter.
  • Across five years, EBIT topped out at $20.0 million in Q4 2025 and bottomed at -$99.3 million in Q3 2023.
  • Average EBIT over 5 years is -$19.2 million, with a median of -$11.0 million recorded in 2024.
  • On a YoY basis, EBIT climbed as much as 326.76% in 2021 and fell as far as 29007.3% in 2021.
  • Celularity's EBIT stood at -$15.0 million in 2021, then soared by 216.95% to $17.5 million in 2022, then decreased by 23.85% to $13.3 million in 2023, then crashed by 169.7% to -$9.3 million in 2024, then surged by 315.32% to $20.0 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $20.0 million, -$12.9 million, and -$15.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.